{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T19:46:02Z","timestamp":1793562362435,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.soncn.2025.151943","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:48:07Z","timestamp":1751424487000},"page":"151943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and Validation of a Patient-Reported Outcome Measure to Assess the Impact of Steroids in the Treatment of Myeloma: The Steroid Symptom Questionnaire\u2013Multiple Myeloma"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9477-2794","authenticated-orcid":false,"given":"Tracy","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Acret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret-Ann","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Jagger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julija","family":"Sipavicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.soncn.2025.151943_bib0001","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.soncn.2025.151943_bib0004","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.soncn.2025.151943_bib0005","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0006","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0007","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/10253890701292119","article-title":"Glucocorticoid action networks and complex psychiatric and\/or somatic disorders","volume":"10","author":"Chrousos","year":"2007","journal-title":"Stress"},{"key":"10.1016\/j.soncn.2025.151943_bib0008","series-title":"Gooodman and Gilman\u2019s the Pharmacological Basis of Therapeutics","author":"Hardman","year":"2001"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","article-title":"From mechanism to resistance - changes in the use of dexamethasone in the treatment of multiple myeloma","volume":"64","author":"Rosenberg","year":"2023","journal-title":"Leuk Lymph"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.soncn.2025.151943_bib0011","article-title":"on behalf of the Myeloma Scientific Advisory Group of Myeloma Australia","author":"Quach","year":"2024","journal-title":"Clinical Practice Guideline Multiple Myeloma"},{"issue":"8","key":"10.1016\/j.soncn.2025.151943_bib0012","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica (Roma)"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0013","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-105-1-8","article-title":"High-dose glucocorticoid treatment of resistant myeloma","volume":"105","author":"Alexanian","year":"1986","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0014","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","article-title":"Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study","volume":"143","author":"Lee","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.blre.2011.03.005","article-title":"Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Review","volume":"25","author":"Palumbo","year":"2011","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0016","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0018","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1188\/17.CJON.240-249","article-title":"Steroid-associated side effects: a symptom management update on multiple myeloma treatment","volume":"21","author":"King","year":"2017","journal-title":"Clin J Oncol Nursing"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0019","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/ajh.27133","article-title":"Association between dexamethasone exposure and visually significant cataracts in multiple myeloma","volume":"99","author":"Banerjee","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.soncn.2025.151943_bib0020","article-title":"Corticosteroid therapy in older adults with cancer: expert recommendations from a task force of the International Society of Geriatric Oncology","author":"Bartsch","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.soncn.2025.151943_bib0021","article-title":"Assessing steroid toxicity in the elderly with multiple myeloma","volume":"134","author":"Nair","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2025.151943_bib0022","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.soncn.2025.151943_bib0023","series-title":"Long-term side effects of glucocorticoids","first-page":"457","author":"Oray","year":"2016"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0024","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11136-016-1435-y","article-title":"Health-related quality of life associated with systemic corticosteroids","volume":"26","author":"Sullivan","year":"2017","journal-title":"Qual Life Res"},{"issue":"10","key":"10.1016\/j.soncn.2025.151943_bib0025","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1176\/appi.ajp.2014.13091264","article-title":"Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects","volume":"171","author":"Judd","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.soncn.2025.151943_bib0026","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study","volume":"18","author":"Mohty","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0027","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"Snowden","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0028","first-page":"E64","article-title":"experiences with multiple myeloma: a meta-aggregation of qualitative studies","volume":"44","author":"Hauksd\u00f3ttir","year":"2017","journal-title":"Oncol Nursing Forum"},{"issue":"6","key":"10.1016\/j.soncn.2025.151943_bib0029","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s11136-019-02392-6","article-title":"How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review","volume":"29","author":"LeBlanc","year":"2020","journal-title":"Qual Life Res"},{"issue":"10","key":"10.1016\/j.soncn.2025.151943_bib0030","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s11136-019-02214-9","article-title":"A systematic review of quality of life research in medicine and health sciences","volume":"28","author":"Haraldstad","year":"2019","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.soncn.2025.151943_bib0031","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/17474086.2019.1634541","article-title":"Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials","volume":"12","author":"Martino","year":"2019","journal-title":"Exp Rev Hematol"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0032","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0033","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1261-6","article-title":"Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS)","volume":"15","author":"Osborne","year":"2015","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.soncn.2025.151943_bib0034","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3324\/haematol.2015.127860","article-title":"Health-related quality of life in patients with multiple myeloma\u2014does it matter?","volume":"100","author":"Kvam","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.soncn.2025.151943_bib0035","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0036","first-page":"417","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0037","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/pon.1710","article-title":"Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners","volume":"20","author":"Molassiotis","year":"2011","journal-title":"Psycho-oncology (Chichester, England)"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0038","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry","volume":"89","author":"Mols","year":"2012","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0039","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.soncn.2025.151943_bib0040","series-title":"Guidance for Industry on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"Food","year":"2009"},{"issue":"8","key":"10.1016\/j.soncn.2025.151943_bib0041","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11136-012-0344-y","article-title":"ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research","volume":"22","author":"Reeve","year":"2013","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.soncn.2025.151943_bib0042","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1188\/07.ONF.673-680","article-title":"Symptom burden: a concept analysis and implications for oncology nurses","volume":"34","author":"Gapstur","year":"2007","journal-title":"Oncol Nursing Forum"},{"key":"10.1016\/j.soncn.2025.151943_bib0043","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1472-6963-13-211","article-title":"A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"10.1016\/j.soncn.2025.151943_bib0044","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s11136-016-1278-6","article-title":"The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations","volume":"25","author":"King","year":"2016","journal-title":"Qual Life Res"},{"issue":"24","key":"10.1016\/j.soncn.2025.151943_bib0045","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.3390\/cancers15245764","article-title":"Guidelines for the use and reporting of patient-reported outcomes in multiple myeloma clinical trials","volume":"15","author":"Laane","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0046","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.soncn.2025.151943_bib0047","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.soncn.2017.05.008","article-title":"Evidence-based guidelines for preventing and managing side effects of multiple myeloma","volume":"33","author":"Bertolotti","year":"2017","journal-title":"Semin Oncol Nurs"},{"issue":"5 Suppl","key":"10.1016\/j.soncn.2025.151943_bib0048","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1188\/17.CJON.S5.19-36","article-title":"Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma","volume":"21","author":"Faiman","year":"2017","journal-title":"Clin J Oncol Nurs"},{"issue":"6","key":"10.1016\/j.soncn.2025.151943_bib0049","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.14514","article-title":"Guidelines for screening and management of late and long-term consequences of myeloma and its treatment","volume":"176","author":"Snowden","year":"2017","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.soncn.2025.151943_bib0050","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.soncn.2025.151943_bib0051","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/hon.2706","article-title":"Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials","volume":"38","author":"Li","year":"2020","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0052","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11899-018-0443-0","article-title":"Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies","volume":"13","author":"McCullough","year":"2018","journal-title":"Curr Hematol Malign Rep"},{"issue":"6","key":"10.1016\/j.soncn.2025.151943_bib0053","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0054","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.soncn.2025.151943_bib0055","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"De Stefano","year":"2022","journal-title":"Haematologica (Roma)"},{"key":"10.1016\/j.soncn.2025.151943_bib0056","unstructured":"PCORI P-CORIMC. Patient-Centered Outcomes Research Institute Methodology Standards. 2019 (Updated February 2019). https:\/\/www.pcori.org\/sites\/default\/files\/PCORI-Methodology-Standards.pdf"},{"key":"10.1016\/j.soncn.2025.151943_bib0057","author":"Johnson"},{"key":"10.1016\/j.soncn.2025.151943_bib0058","series-title":"Development and evaluation of a patient-reported outcome measure (PROM) to assess the impact of steroids associated with therapy for multiple myeloma. Doctorate dissertation","author":"King","year":"2021"},{"issue":"9","key":"10.1016\/j.soncn.2025.151943_bib0059","first-page":"2789","article-title":"Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life","volume":"23","author":"Baz","year":"2015","journal-title":"Supp Care Cancer"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0060","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-496","article-title":"Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life","volume":"14","author":"Osborne","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.soncn.2025.151943_bib0061","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.soncn.2025.151943_bib0062","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"94","author":"Vardy","year":"2006","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0063","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10549-012-2205-3","article-title":"A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer","volume":"136","author":"Vardy","year":"2012","journal-title":"Breast Cancer Res Treatment"},{"issue":"3","key":"10.1016\/j.soncn.2025.151943_bib0064","first-page":"1209","article-title":"Validating self-report and proxy reports of the Dexamethasone Symptom Questionnaire-Chronic for the evaluation of longer-term corticosteroid toxicity","volume":"24","author":"Agar","year":"2016","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"5","key":"10.1016\/j.soncn.2025.151943_bib0066","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","article-title":"COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study","volume":"27","author":"Terwee","year":"2018","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.soncn.2025.151943_bib0067","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","article-title":"The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes","volume":"63","author":"Mokkink","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.soncn.2025.151943_bib0068","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0069","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1744-6155.2008.00171.x","article-title":"Scientific inquiry precision, reliability, and validity: essential elements of measurement in nursing research","volume":"13","author":"Houser","year":"2008","journal-title":"J Specialists Pediatr Nursing"},{"issue":"5","key":"10.1016\/j.soncn.2025.151943_bib0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.soncn.2025.151943_bib0071","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","article-title":"Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust","volume":"69","author":"Giesinger","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.soncn.2025.151943_bib0072","series-title":"Assessing Quality of Life in Clinical Trials: Methods and Practice","article-title":"Developing questionnaires","author":"McColl","year":"2005"},{"key":"10.1016\/j.soncn.2025.151943_bib0073","series-title":"Psychometric Theory","author":"Nunnally","year":"1994"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0074","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.2517-6161.1954.tb00174.x","article-title":"A note on the multiplying factors for various \u03c72 approximations","volume":"16","author":"Bartlett","year":"1954","journal-title":"J R Stat Soc Ser B (Methodol)"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02291575","article-title":"An index of factorial simplicity","volume":"39","author":"Kaiser","year":"1974","journal-title":"Psychometrika"},{"issue":"3","key":"10.1016\/j.soncn.2025.151943_bib0076","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","article-title":"User's guide to correlation coefficients","volume":"18","author":"Akoglu","year":"2018","journal-title":"Turk J Emerg Med"},{"issue":"7","key":"10.1016\/j.soncn.2025.151943_bib0077","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","article-title":"The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use","volume":"103","author":"Manson","year":"2009","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.soncn.2025.151943_bib0078","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0079","doi-asserted-by":"crossref","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"10","key":"10.1016\/j.soncn.2025.151943_bib0080","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Therap"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0081","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","article-title":"Corticosteroid-induced clinical adverse events: frequency, risk factors and patient\u2019s opinion","volume":"157","author":"Fardet","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0082","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.psym.2011.12.007","article-title":"The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited","volume":"53","author":"Dubovsky","year":"2012","journal-title":"Psychosomatics"},{"issue":"5","key":"10.1016\/j.soncn.2025.151943_bib0083","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ajp.2011.11071009","article-title":"Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care","volume":"169","author":"Fardet","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0084","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2133.2010.09877.x","article-title":"Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy","volume":"163","author":"Arena","year":"2010","journal-title":"Br J Dermatol"},{"issue":"29","key":"10.1016\/j.soncn.2025.151943_bib0085","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.2217\/fon-2017-0306","article-title":"Steroid-induced mental disorders in cancer patients: a systematic review","volume":"13","author":"Ismail","year":"2017","journal-title":"Fut Oncol (London, Engl)"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0086","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaad.2016.02.1239","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.soncn.2025.151943_bib0087","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJM195202072460601","article-title":"Preliminary observations on mental disturbances occurring in patients under therapy with cortisone and ACTH","volume":"246","author":"Clark","year":"1952","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2025.151943_bib0088","series-title":"Psychiatric Complications of Treatment With Corticosteroids: Review With Case Report","first-page":"549","author":"Kenna","year":"2011"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0089","first-page":"87","article-title":"Psychological and psychiatric sequelae of steroid use in hematology treatments: a review of the literature","volume":"6","author":"McGrath","year":"2007","journal-title":"Asian Journal of Cancer"},{"key":"10.1016\/j.soncn.2025.151943_bib0090","series-title":"Psychiatric Adverse Effects of Corticosteroids","first-page":"1361","author":"Warrington","year":"2006"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0091","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MOT.0000000000000065","article-title":"Strategies to prevent the neuropsychiatric side-effects of corticosteroids: a case report and review of the literature","volume":"19","author":"West","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0092","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1749-6632.2009.04980.x","article-title":"Glucocorticoids: mood, memory, and mechanisms","volume":"1179","author":"Wolkowitz","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0093","first-page":"339","article-title":"I was never like that\u201d: Australian findings on the psychological and psychiatric sequelae of corticosteroids in haematology treatments","volume":"17","author":"McGrath","year":"2009","journal-title":"Supp Care Cancer"},{"issue":"10","key":"10.1016\/j.soncn.2025.151943_bib0094","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00002018-200730100-00005","article-title":"Corticosteroid-induced adverse events in adults: frequency, screening and prevention","volume":"30","author":"Fardet","year":"2007","journal-title":"Drug Safety"},{"issue":"14","key":"10.1016\/j.soncn.2025.151943_bib0095","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1110307","article-title":"Suicide and cardiovascular death after a cancer diagnosis","volume":"366","author":"Fang","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.soncn.2025.151943_bib0096","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.soncn.2017.05.006","article-title":"Patient reported outcomes in optimizing myeloma patients' health-related quality of life","volume":"33","author":"King","year":"2017","journal-title":"Semin Oncol Nursing"},{"issue":"11","key":"10.1016\/j.soncn.2025.151943_bib0097","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer (1990)"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0098","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1207\/s15327906mbr0102_10","article-title":"The Scree test for the number of factors","volume":"1","author":"Cattell","year":"1966","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.soncn.2025.151943_bib0099","series-title":"Nijkamp and Parnham's Principles of Immunopharmacology","first-page":"661","article-title":"M. Corticosteroids","author":"Caramori","year":"2019"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/01460860903486572","article-title":"Corticosteroids during continuation therapy for acute lymphoblastic leukemia: the psycho-social impact","volume":"33","author":"McGrath","year":"2010","journal-title":"Iss Comprehens Pediatr Nursing"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0101","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/01312067-200902010-00003","article-title":"This is not me, it's the drug\": coping with the psychological impact of corticosteroid treatments in hematology. Further results from a pilot study","volume":"2","author":"McGrath","year":"2009","journal-title":"Patient: Patient-Centered Outcomes Research"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0102","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2141.2011.08703.x","article-title":"A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients","volume":"154","author":"Sher","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.2024025939","article-title":"Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis","volume":"145","author":"Banerjee","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.soncn.2025.151943_bib0104","first-page":"2075","article-title":"Patient-reported outcomes in relapsed\/refractory multiple myeloma: a systematic review","volume":"26","author":"Sparano","year":"2018","journal-title":"Supp Care Cancer"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"issue":"28","key":"10.1016\/j.soncn.2025.151943_bib0106","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7748\/ns.25.28.38.s53","article-title":"Patients' lived experiences of myeloma","volume":"25","author":"Kelly","year":"2011","journal-title":"Nursing Stand"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0107","first-page":"267","article-title":"An exploration of the lived experiences of individuals with relapsed multiple myeloma","volume":"20","author":"Maher","year":"2011","journal-title":"Eur J Cancer Care"},{"issue":"18 Suppl","key":"10.1016\/j.soncn.2025.151943_bib0108","article-title":"The time taken to complete quality of life questionnaires in an advanced cancer trial","volume":"24","author":"Stockler","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0109","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/dmrr.2486","article-title":"Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment","volume":"30","author":"Hwang","year":"2014","journal-title":"Diab Metab Res Rev"},{"issue":"5","key":"10.1016\/j.soncn.2025.151943_bib0110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/0269216319833588","article-title":"Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: a prospective, multi-centre longitudinal study","volume":"33","author":"Ramsenthaler","year":"2019","journal-title":"Palliat Med"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0111","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France","volume":"19","author":"Despi\u00e9gel","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1016\/j.soncn.2025.151943_bib0112","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2939.2939","article-title":"Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) improves health-related quality of life (HRQoL) vs high-dose dexamethasone (HiDEX) in relapsed refractory multiple myeloma (RRMM) patients enrolled in MM-003 phase 3 randomized trial","volume":"122","author":"Song","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0113","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0165-0327(83)90022-8","article-title":"Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature","volume":"5","author":"Lewis","year":"1983","journal-title":"J Affect Disord"},{"issue":"4","key":"10.1016\/j.soncn.2025.151943_bib0114","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","article-title":"Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy","volume":"107","author":"Facon","year":"2006","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.soncn.2025.151943_bib0115","article-title":"Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du My\u00e9lome (IFM)","volume":"41","author":"Touzeau","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.soncn.2025.151943_bib0116","article-title":"The IFM2017-03 phase 3 trial: a dexamethasone sparing-regimen with daratumumab and lenalidomide for frail patients with newly-diagnosed multiple myeloma","volume":"144","author":"Manier","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.soncn.2025.151943_bib0117","first-page":"3979","article-title":"Side effects of corticosteroids in patients with advanced cancer: a systematic review","volume":"26","author":"Hatano","year":"2018","journal-title":"Supp Care Cancer"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0118","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/nhs.12395","article-title":"Psychiatric sequelae of corticosteroid use in hematology in Australia: a qualitative study","volume":"20","author":"Clifton","year":"2018","journal-title":"Nursing Health Sci"},{"issue":"5","key":"10.1016\/j.soncn.2025.151943_bib0119","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/MLR.0000000000001089","article-title":"A PRO-cision medicine methods toolkit to address the challenges of personalizing cancer care using patient-reported outcomes: introduction to the supplement","volume":"57","author":"Snyder","year":"2019","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0120","first-page":"41","article-title":"Patient-reported outcome use in oncology: a systematic review of the impact on patient-clinician communication","volume":"26","author":"Yang","year":"2018","journal-title":"Supp Care Cancer"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0121","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.2024026814","article-title":"Down with dex!","volume":"145","author":"Harding","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0122","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/hex.12997","article-title":"Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials","volume":"23","author":"Addario","year":"2020","journal-title":"Health Expect"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0123","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMp1611252","article-title":"Patient-reported outcomes - harnessing patients' voices to improve clinical care","volume":"376","author":"Basch","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.soncn.2025.151943_bib0124","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-11-95","article-title":"Development and validation of a new patient-reported outcome measure for patients with pressure ulcers: the PU-QOL instrument","volume":"11","author":"Gorecki","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.soncn.2025.151943_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(23)02110-9","article-title":"Characterising sleep disturbances with actigraphy in those receiving steroids for the treatment of multiple myeloma: findings from a pilot study","volume":"23","author":"King","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"2","key":"10.1016\/j.soncn.2025.151943_bib0126","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","article-title":"Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial","volume":"12","author":"Askeland","year":"2025","journal-title":"Lancet Haematol"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208125001366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208125001366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:11:25Z","timestamp":1760220685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208125001366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0749208125001366"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2025.151943","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and Validation of a Patient-Reported Outcome Measure to Assess the Impact of Steroids in the Treatment of Myeloma: The Steroid Symptom Questionnaire\u2013Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2025.151943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151943"}}